Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
D Jakimovski, B Weinstock-Guttman… - Expert opinion on …, 2017 - Taylor & Francis
Introduction. Multiple sclerosis (MS) is the most common neurological disease responsible
for early disability in the young working population. In the last two decades, based on …
for early disability in the young working population. In the last two decades, based on …
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
D Jakimovski, B Weinstock-Guttman… - Expert Opinion on …, 2017 - europepmc.org
Multiple sclerosis (MS) is the most common neurological disease responsible for early
disability in the young working population. In the last two decades, based on retrospective …
disability in the young working population. In the last two decades, based on retrospective …
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
D Jakimovski, B Weinstock-Guttman… - Expert opinion on …, 2017 - pubmed.ncbi.nlm.nih.gov
Multiple sclerosis (MS) is the most common neurological disease responsible for early
disability in the young working population. In the last two decades, based on retrospective …
disability in the young working population. In the last two decades, based on retrospective …